Tremfya rescues J&J’s immunology sales to fuel strong Q3
Johnson & Johnson (J&J) leaned on strong demand for anti-inflammatory drug Tremfya (guselkumab) to offset steep erosion in other areas…
13 Oct 2026
Roche bets on the RNAi approach for obesity through $1bn Rona deal
Roche has made another bid to enter the increasingly lucrative obesity arena through a licensing deal centred around an RNA interference (RNAi) therapy created by Rona Therapeutics – marking the…
13 Oct 2026
China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
China's National Medical Products Administration (NMPA) has approved the marketing authorisation application (MAA) for Foresee Pharmaceuticals’ Camcevi 42 mg to treat adult patients with advanced prostate cancer. The company was…
13 Oct 2026
Southern Research secures NIH funding for drug testing hub
Southern Research has secured an $8m grant from the US National Institutes of Health (NIH) to establish a national shared-use biomedical facility, the Translational Hub for Research, Innovation, Validation, and…
12 Oct 2026
FDA approves Teva’s monthly injection of olanzapine for schizophrenia
The most widely used atypical antipsychotic is now available as a once-monthly injection for schizophrenia patients after a US Food and Drug Administration (FDA) approval. Teva’s olanzapine, which has been…
12 Oct 2026
FDA approves Asahi Kasei’s Hovilpri for refractory HSV
The US Food and Drug Administration (FDA) has approved Asahi Kasei Therapeutics’ Hovilpri (pritelivir) 100mg tablets to treat refractory mucocutaneous herpes simplex virus (HSV) lesions in immunocompromised adults. This oral…
12 Oct 2026
Perceptive, Nucleus partner to support radiopharmaceutical development
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist radiopharmaceutical developers shift from initial target validation through to clinical manufacturing. Under the terms of the agreement, the…